Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies

Cancer Cell

Volumn 27, Issue 1, 2015, Pages 138-148

  White, Ann L ^a   Chan, H T Claude ^a   French, Ruth R ^a   Willoughby, Jane ^a   Mockridge, C Ian ^a   Roghanian, Ali ^a   Penfold, Christine A ^a   Booth, Steven G ^a   Dodhy, Ali ^a   Polak, Marta E ^a   Potter, Elizabeth A ^a   Ardern Jones, Michael R ^a   Verbeek, J Sjef ^b   Johnson, Peter W M ^a   Al Shamkhani, Aymen ^a   Cragg, Mark S ^a   Beers, Stephen A ^a   Glennie, Martin J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY CD28; CD137 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CONFORMATION; CONTROLLED STUDY; DISULFIDE BOND; GENETIC ENGINEERING; HINGE REGION; IMMUNOMODULATION; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; HUMAN; IMMUNOLOGY; PROCEDURES; THYMOMA; THYMUS NEOPLASMS; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD137; ANTIGENS, CD28; ANTIGENS, CD40; CELLS, CULTURED; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; RECEPTORS, IGG; THYMOMA; THYMUS NEOPLASMS; VACCINATION;

EID: 84922189761     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.11.001     Document Type: Article

References (62)

1. Advani, R., Forero-Torres, A., Furman, R.R., Rosenblatt, J.D., Younes, A., Ren, H., Harrop, K., Whiting, N., and Drachman, J.G. (2009). Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27, 4371-4377.
2. Ahonen, C., Manning, E., Erickson, L.D., O'Connor, B., Lind, E.F., Pullen, S.S., Kehry, M.R., and Noelle, R.J. (2002). The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells. Nat. Immunol. 3, 451-456.
3. Allen, M.J., Guo, A., Martinez, T., Han, M., Flynn, G.C., Wypych, J., Liu, Y.D., Shen, W.D., Dillon, T.M., Vezina, C., and Balland, A. (2009). Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis. Biochemistry 48, 3755-3766.
4. Angal, S., King, D.J., Bodmer, M.W., Turner, A., Lawson, A.D., Roberts, G., Pedley, B., and Adair, J.R. (1993). A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody. Mol. Immunol. 30, 105-108.
5. Bajor, D.L., Xu, X., Torigian, D.A., Mick, R., Garcia, L.R., Richman, L.P., Desmarais, C., Nathanson, K.L., Schuchter, L.M., Kalos, M., and Vonderheide, R.H. (2014). Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. Cancer Immunol. Res. 2, 1051-1058.
6. Barrett, D.J., and Ayoub, E.M. (1986). IgG2 subclass restriction of antibody to pneumococcal polysaccharides. Clin. Exp. Immunol. 63, 127-134.
7. Bartholomaeus, P., Semmler, L.Y., Bukur, T., Boisguerin, V., Römer, P.S., Tabares, P., Chuvpilo, S., Tyrsin, D.Y., Matskevich, A., Hengel, H., et al. (2014). Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response. J. Immunol. 192, 2091-2098.
8. Beatty, G.L., Chiorean, E.G., Fishman, M.P., Saboury, B., Teitelbaum, U.R., Sun, W., Huhn, R.D., Song, W., Li, D., Sharp, L.L., et al. (2011). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616.
9. Beatty, G.L., Torigian, D.A., Chiorean, E.G., Saboury, B., Brothers, A., Alavi, A., Troxel, A.B., Sun, W., Teitelbaum, U.R., Vonderheide, R.H., and O'Dwyer, P.J. (2013). A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin. Cancer Res. 19, 6286-6295.
10. Boross, P., Arandhara, V.L., Martin-Ramirez, J., Santiago-Raber, M.L., Carlucci, F., Flierman, R., van der Kaa, J., Breukel, C., Claassens, J.W., Camps, M., et al. (2011). The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility. J. Immunol. 187, 1304-1313.
11. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465.
12. Bruhns, P., Iannascoli, B., England, P., Mancardi, D.A., Fernandez, N., Jorieux, S., and Daëron, M. (2009). Specificity and affinity of human Fcγamma receptors and their polymorphic variants for human IgG subclasses. Blood 113, 3716-3725.
13. Bulliard, Y., Jolicoeur, R., Windman, M., Rue, S.M., Ettenberg, S., Knee, D.A., Wilson, N.S., Dranoff, G., and Brogdon, J.L. (2013). Activating Fc g receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J. Exp. Med. 210, 1685-1693.
14. Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N.S., and Brogdon, J.L. (2014). OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy. Immunol. Cell Biol. 92, 475-480.
15. Chowdhury, F., Johnson, P.W., Glennie, M.J., and Williams, A.P. (2014). Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial. Cancer Immunol. Res. 2, 229-240.
16. Chu, S.Y., Vostiar, I., Karki, S., Moore, G.L., Lazar, G.A., Pong, E., Joyce, P.F., Szymkowski, D.E., and Desjarlais, J.R. (2008). Inhibition of B cell receptormediated activation of primary human B cells by coengagement of CD19 and FcγammaRIIb with Fc-engineered antibodies. Mol. Immunol. 45, 3926- 3933.
17. Clynes, R.A., Towers, T.L., Presta, L.G., and Ravetch, J.V. (2000). Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat. Med. 6, 443-446.
18. Drachman, J., Law, C.-L., and Lewis, T. May 2007. Methods of using CD40 binding agents. U.S. patent WO/2007/075326.
19. Dillon, T.M., Ricci, M.S., Vezina, C., Flynn, G.C., Liu, Y.D., Rehder, D.S., Plant, M., Henkle, B., Li, Y., Deechongkit, S., et al. (2008). Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J. Biol. Chem. 283, 16206-16215.
20. Elgueta, R., Benson, M.J., de Vries, V.C., Wasiuk, A., Guo, Y., and Noelle, R.J. (2009). Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol. Rev. 229, 152-172.
21. French, R.R., Chan, H.T., Tutt, A.L., and Glennie, M.J. (1999). CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5, 548-553.
22. French, R.R., Taraban, V.Y., Crowther, G.R., Rowley, T.F., Gray, J.C., Johnson, P.W., Tutt, A.L., Al-Shamkhani, A., and Glennie, M.J. (2007). Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 109, 4810-4815.
23. Greenman, J., Tutt, A.L., George, A.J., Pulford, K.A., Stevenson, G.T., and Glennie, M.J. (1991). Characterization of a new monoclonal anti-Fc gamma RII antibody, AT10, and its incorporation into a bispecific F(ab0)2 derivative for recruitment of cytotoxic effectors. Mol. Immunol. 28, 1243-1254.
24. Guo, A., Han, M., Martinez, T., Ketchem, R.R., Novick, S., Jochheim, C., and Balland, A. (2008). Electrophoretic evidence for the presence of structural isoforms specific for the IgG2 isotype. Electrophoresis 29, 2550-2556.
25. Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., and Tedder, T.F. (2006). Antibody isotype-specific engagement of Fcγamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J. Exp. Med. 203, 743-753.
26. Hanke, T., Trischler, M., and Guntermann, C. September 2009. Encoding a binding molecule specifically binding to a human CD28 molecule; comprising a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region with CDRs in a human immunoglobulin framework. U.S. patent US7585960.
27. Hanks, B.A., Jiang, J., Singh, R.A., Song, W., Barry, M., Huls, M.H., Slawin, K.M., and Spencer, D.M. (2005). Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat. Med. 11, 130-137.
28. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
29. Kohrt, H.E., Houot, R., Goldstein, M.J., Weiskopf, K., Alizadeh, A.A., Brody, J., Müller, A., Pachynski, R., Czerwinski, D., Coutre, S., et al. (2011). CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117, 2423-2432.
30. Kohrt, H.E., Houot, R., Weiskopf, K., Goldstein, M.J., Scheeren, F., Czerwinski, D., Colevas, A.D., Weng, W.K., Clarke, M.F., Carlson, R.W., et al. (2012). Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J. Clin. Invest. 122, 1066-1075.
31. Kohrt, H.E., Colevas, A.D., Houot, R., Weiskopf, K., Goldstein, M.J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., et al. (2014). Targeting CD137 enhances the efficacy of cetuximab. J. Clin. Invest. 124, 2668-2682.
32. Kurai, J., Chikumi, H., Hashimoto, K., Yamaguchi, K., Yamasaki, A., Sako, T., Touge, H., Makino, H., Takata, M., Miyata, M., et al. (2007). Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res. 13, 1552-1561.
33. Li, F., and Ravetch, J.V. (2011). Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science 333, 1030-1034.
34. Li, F., and Ravetch, J.V. (2012). Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement. Proc. Natl. Acad. Sci. USA 109, 10966-10971.
35. Li, F., and Ravetch, J.V. (2013). Antitumor activities of agonistic anti-TNFR antibodies require differential FcγRIIB coengagement in vivo. Proc. Natl. Acad. Sci. USA 110, 19501-19506.
36. Lightle, S., Aykent, S., Lacher, N., Mitaksov, V., Wells, K., Zobel, J., and Oliphant, T. (2010). Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. Protein Sci. 19, 753-762.
37. Liu, Y.D., Chen, X., Enk, J.Z., Plant, M., Dillon, T.M., and Flynn, G.C. (2008). Human IgG2 antibody disulfide rearrangement in vivo. J. Biol. Chem. 283, 29266-29272.
38. Lux, A., Yu, X., Scanlan, C.N., and Nimmerjahn, F. (2013). Impact of immune complex size and glycosylation on IgG binding to human FcγRs. J. Immunol. 190, 4315-4323.
39. Martinez, T., Guo, A., Allen, M.J., Han, M., Pace, D., Jones, J., Gillespie, R., Ketchem, R.R., Zhang, Y., and Balland, A. (2008). Disulfide connectivity of human immunoglobulin G2 structural isoforms. Biochemistry 47, 7496-7508.
40. Moran, A.E., Kovacsovics-Bankowski, M., and Weinberg, A.D. (2013). The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr. Opin. Immunol. 25, 230-237.
41. Nimmerjahn, F., and Ravetch, J.V. (2005). Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310, 1510-1512.
42. Nimmerjahn, F., and Ravetch, J.V. (2012). Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun. 12, 13-19.
43. Richman, L.P., and Vonderheide, R.H. (2014). Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer. Cancer Immunol. Res. 2, 19-26.
44. Ryazantsev, S., Tischenko, V., Nguyen, C., Abramov, V., and Zav'yalov, V. (2013). Three-dimensional structure of the human myeloma IgG2. PLoS ONE 8, e64076.
45. Sanchez, P.J., McWilliams, J.A., Haluszczak, C., Yagita, H., and Kedl, R.M. (2007). Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J. Immunol. 178, 1564-1572.
46. Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. (2013). Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695- 1710.
47. Sliwkowski, M.X., and Mellman, I. (2013). Antibody therapeutics in cancer. Science 341, 1192-1198.
48. Smulski, C.R., Beyrath, J., Decossas, M., Chekkat, N., Wolff, P., Estieu- Gionnet, K., Guichard, G., Speiser, D., Schneider, P., and Fournel, S. (2013). Cysteine-rich domain 1 of CD40 mediates receptor self-assembly. J. Biol. Chem. 288, 10914-10922.
49. Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D., and Panoskaltsis, N. (2006). Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028.
50. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
51. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., and Tedder, T.F. (2004). The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199, 1659-1669.
52. Vonderheide, R.H., and Glennie, M.J. (2013). Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035-1043.
53. White, A.L., Tutt, A.L., James, S., Wilkinson, K.A., Castro, F.V., Dixon, S.V., Hitchcock, J., Khan, M., Al-Shamkhani, A., Cunningham, A.F., and Glennie, M.J. (2010). Ligation of CD11c during vaccination promotes germinal centre induction and robust humoral responses without adjuvant. Immunology 131, 141-151.
54. White, A.L., Chan, H.T., Roghanian, A., French, R.R., Mockridge, C.I., Tutt, A.L., Dixon, S.V., Ajona, D., Verbeek, J.S., Al-Shamkhani, A., et al. (2011). Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J. Immunol. 187, 1754-1763.
55. White, A.L., Chan, H.T., French, R.R., Beers, S.A., Cragg, M.S., Johnson, P.W., and Glennie, M.J. (2013). FcγRIIB controls the potency of agonistic anti-TNFR mAbs. Cancer Immunol. Immunother. 62, 941-948.
56. White, A.L., Dou, L., Chan, H.T.C., Field, V.L., Mockridge, C.I., Moss, K., Williams, E., Butts, C., Al-Shamkhani, A., Cragg, M.S., et al. (2014). FcR dependence of agonistic CD40 antibody is related to anatomical location and can be overcome by antibody multimerisation. J. Immunol. 193, 1828- 1835.
57. Wilson, N.S., Yang, B., Yang, A., Loeser, S., Marsters, S., Lawrence, D., Li, Y., Pitti, R., Totpal, K., Yee, S., et al. (2011). An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19, 101-113.
58. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. (2013). Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122-133.
59. Wypych, J., Li, M., Guo, A., Zhang, Z., Martinez, T., Allen, M.J., Fodor, S., Kelner, D.N., Flynn, G.C., Liu, Y.D., et al. (2008). Human IgG2 antibodies display disulfide-mediated structural isoforms. J. Biol. Chem. 283, 16194- 16205.
60. Xu, Y., Szalai, A.J., Zhou, T., Zinn, K.R., Chaudhuri, T.R., Li, X., Koopman, W.J., and Kimberly, R.P. (2003). Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics. J. Immunol. 171, 562-568.
61. Yoo, E.M., Wims, L.A., Chan, L.A., and Morrison, S.L. (2003). Human IgG2 can form covalent dimers. J. Immunol. 170, 3134-3138.
62. Zhang, B., Harder, A.G., Connelly, H.M., Maheu, L.L., and Cockrill, S.L. (2010). Determination of Fab-hinge disulfide connectivity in structural isoforms of a recombinant human immunoglobulin G2 antibody. Anal. Chem. 82, 1090-1099.